Theravance Biopharma Inc (NASDAQ:TBPH) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 3,300,000 shares, a decline of 7.0% from the August 30th total of 3,550,000 shares. Based on an average daily trading volume, of 246,400 shares, the days-to-cover ratio is presently 13.4 days. Approximately 7.7% of the shares of the stock are sold short.
A number of research firms have weighed in on TBPH. BidaskClub lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Friday, October 11th. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Theravance Biopharma in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $44.25.
Shares of NASDAQ TBPH opened at $17.17 on Friday. Theravance Biopharma has a 12 month low of $15.18 and a 12 month high of $30.34. The firm has a market capitalization of $974.16 million, a price-to-earnings ratio of -4.30 and a beta of 1.64. The business has a 50-day moving average of $20.55 and a 200-day moving average of $20.02.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Simplex Trading LLC grew its holdings in shares of Theravance Biopharma by 30.1% during the third quarter. Simplex Trading LLC now owns 5,043 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,167 shares in the last quarter. Opti Capital Management LP purchased a new position in shares of Theravance Biopharma during the second quarter worth about $1,303,000. Northern Trust Corp grew its holdings in shares of Theravance Biopharma by 0.6% during the second quarter. Northern Trust Corp now owns 553,629 shares of the biopharmaceutical company’s stock worth $9,041,000 after purchasing an additional 3,547 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Theravance Biopharma by 64.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after purchasing an additional 7,500 shares in the last quarter. Finally, CWM Advisors LLC purchased a new position in shares of Theravance Biopharma during the second quarter worth about $167,000. 84.16% of the stock is owned by institutional investors.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Featured Article: What is Compound Interest?
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.